\-\ Texto\\:\\ \ \(0\)\
\-\ bilateral\\ leg\\ weakness\\ and\\ absent\\ reflexes\\.\ \(0\)\
\-\ chemotherapy\\ and\\ radiation\\.\ \(3\)\
\-\ infiltrative\\ intramedullary\\ lesion\\ extending\\ from\\ t3\\ to\\ the\\ conus\\.\\ \\ the\\ mass\\ demonstrates\\ irregular\\ enhancement\\ after\\ contrast\\ administration\\.\ \(0\)\
\-\ spinal\\ cord\\ astrocytoma\\,\\ malignant\ \(0\)\
\-\ astrocytoma\ \(206\)\
\-\ ependymoma\ \(74\)\
\-\ hemangioblastoma\ \(37\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ 12\\ year\\ old\\ girl\\ with\\ progressive\\ back\\ pain\\ and\\ leg\\ weakness\\ over\\ the\\ past\\ 3\\ months\\.\\ \\ no\\ urinary\\ or\\ rectal\\ incontinence\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ leg\\:\\ 0\\.10667293043202529\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.1053444507515332\ \(0\)\
\-\ weakness\\:\\ 0\\.10074956676280584\ \(0\)\
\-\ t3\\:\\ 0\\.08761399298352648\ \(0\)\
\-\ intramedullary\\:\\ 0\\.08395488729127518\ \(0\)\
\-\ conus\\:\\ 0\\.08177709171169606\ \(0\)\
\-\ incontinence\\:\\ 0\\.08022727473449104\ \(0\)\
\-\ infiltrative\\:\\ 0\\.07783326061171987\ \(0\)\
\-\ rectal\\:\\ 0\\.07690835730816471\ \(0\)\
\-\ hemangioblastoma\\:\\ 0\\.07493926764673647\ \(0\)\
\-\ reflexes\\:\\ 0\\.06420371110318783\ \(0\)\
\-\ urinary\\:\\ 0\\.06278898443817184\ \(0\)\
\-\ ependymoma\\:\\ 0\\.06071564820932955\ \(0\)\
\-\ absent\\:\\ 0\\.05878620056523738\ \(0\)\
\-\ administration\\:\\ 0\\.05631206769687571\ \(0\)\
\-\ 12\\:\\ 0\\.05551426079559177\ \(0\)\
\-\ irregular\\:\\ 0\\.05410074051597427\ \(0\)\
\-\ progressive\\:\\ 0\\.05361014468322702\ \(0\)\
\-\ cord\\:\\ 0\\.05154244317786351\ \(0\)\
\-\ malignant\\:\\ 0\\.049026518672687314\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.048618187065728014\ \(0\)\
\-\ spinal\\:\\ 0\\.04856787635523152\ \(0\)\
\-\ girl\\:\\ 0\\.04768853065063171\ \(0\)\
\-\ extending\\:\\ 0\\.04559871506094916\ \(0\)\
\-\ back\\:\\ 0\\.04474708468805519\ \(0\)\
\-\ radiation\\:\\ 0\\.04451192459622756\ \(0\)\
\-\ past\\:\\ 0\\.043098404316610064\ \(0\)\
\-\ months\\:\\ 0\\.03704668721730265\ \(0\)\
\-\ enhancement\\:\\ 0\\.03635696454163549\ \(0\)\
\-\ over\\:\\ 0\\.03453400936730099\ \(0\)\
\-\ metastatic\\:\\ 0\\.03414459370819191\ \(0\)\
\-\ bilateral\\:\\ 0\\.0329177417351499\ \(0\)\
\-\ 3\\:\\ 0\\.0317615162969292\ \(0\)\
\-\ contrast\\:\\ 0\\.03036151883822072\ \(0\)\
\-\ demonstrates\\:\\ 0\\.029628907962748984\ \(0\)\
\-\ after\\:\\ 0\\.02806351115252702\ \(0\)\
\-\ lesion\\:\\ 0\\.027627860730165946\ \(0\)\
\-\ disease\\:\\ 0\\.022170437162154034\ \(0\)\
\-\ from\\:\\ 0\\.02010215417705099\ \(0\)\
\-\ mass\\:\\ 0\\.018864460427739118\ \(0\)\
\-\ pain\\:\\ 0\\.01656520900842436\ \(0\)\
\-\ or\\:\\ 0\\.01589718649148742\ \(0\)\
\-\ year\\:\\ 0\\.01517627411544309\ \(0\)\
\-\ old\\:\\ 0\\.01388785074384531\ \(0\)\
\-\ no\\:\\ 0\\.01365784366196511\ \(0\)\
\-\ and\\:\\ 0\\.008571857415819926\ \(0\)\
\-\ to\\:\\ 0\\.006778858864174384\ \(0\)\
\-\ the\\:\\ 0\\.006583299271601228\ \(0\)\
\-\ \\,\\:\\ 0\\.004296985166941069\ \(0\)\
\-\ \\.\\:\\ 0\\.003380908199747264\ \(0\)\
\-\ with\\:\\ 0\\.001857209144283964\ \(0\)\
